Literature DB >> 16088966

The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.

J Matthew McDonald1, Siew Ju See, Ivo W Tremont, Howard Colman, Mark R Gilbert, Morris Groves, Peter C Burger, David N Louis, Caterina Giannini, Gregory Fuller, Sandra Passe, Hilary Blair, Robert B Jenkins, Helen Yang, Alicia Ledoux, Joann Aaron, Ulka Tipnis, Wei Zhang, Kenneth Hess, Ken Aldape.   

Abstract

BACKGROUND: It has been reported previously that the combined loss of chromosomal arms 1p and 19q is a significant predictor of outcome for patients with anaplastic oligodendroglial (AO) tumors and that such chromosomal loss correlates with classic histology in AO. The authors sought to determine whether histology was an equivalent or superior predictor of outcome compared with 1p/19q status in 131 patients with AO tumors.
METHODS: The status of 1p and 19q was determined using real-time, quantitative polymerase chain reaction analysis and/or fluorescence in situ hybridization. Clinical features (response to adjuvant therapy and tumor location) and molecular genetic abnormalities (9p and 10q deletions, overexpression of p53 and epidermal growth factor receptor) were determined on available specimens. Histologic assessments for classic oligodendroglial features were performed by five neuropathologists.
RESULTS: Classic histology was associated closely with 1p/19q loss, as reported previously. Patients who had tumors that were considered classic by at least four of the five neuropathologists showed significantly increased progression-free and overall survival compared with the patients who had less classic tumors. The authors also tested the correlation between 1p/19q status and outcome in subsets of patients stratified according to classic tumor features. The association of 1p/19q status with survival was related closely to the presence of classic histology. Loss of 1p/19q was predictive of improved outcome only among patients who had tumors with classic histologic features.
CONCLUSIONS: The current results suggested that, in addition to 1p/19q status, histologic features contribute information to the prediction of outcome in patients with AO. Loss of 1p and 19q appeared to be a prognostic marker only in the subset of patients who had AO tumors with classic histologic features.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16088966     DOI: 10.1002/cncr.21338

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  36 in total

1.  Anaplastic glioma.

Authors:  Nina A Paleologos; Ryan T Merrell
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

2.  Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics.

Authors:  Mahfoud Assem; Zita Sibenaller; Supreet Agarwal; Maha S Al-Keilani; Mohammad A Y Alqudah; Timothy C Ryken
Journal:  OMICS       Date:  2012-03

3.  Detection of intratumoral calcification in oligodendrogliomas by susceptibility-weighted MR imaging.

Authors:  M Zulfiqar; N Dumrongpisutikul; J Intrapiromkul; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

4.  Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma.

Authors:  Alba A Brandes; Linda Nicolardi; Alicia Tosoni; Marina Gardiman; Paolo Iuzzolino; Claudio Ghimenton; Michele Reni; Antonino Rotilio; Guido Sotti; Mario Ermani
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

Review 5.  Management of newly diagnosed glioblastoma: guidelines development, value and application.

Authors:  Jeffrey J Olson; Camilo E Fadul; Daniel J Brat; Srinivasan Mukundan; Timothy C Ryken
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

6.  Diagnosis of malignant glioma: role of neuropathology.

Authors:  Daniel J Brat; Richard A Prayson; Timothy C Ryken; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

7.  Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth.

Authors:  Chibo Hong; K Scott Moorefield; Peter Jun; Kenneth D Aldape; Samir Kharbanda; Heidi S Phillips; Joseph F Costello
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

8.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

9.  Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients.

Authors:  Fausto J Rodriguez; Tarik Tihan; Doris Lin; William McDonald; Janice Nigro; Burt Feuerstein; Sadhana Jackson; Kenneth Cohen; Peter C Burger
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

10.  Success at last: a molecular factor that informs treatment.

Authors:  Andrew B Lassman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.